Jpmorgan Chase & CO Landec Corp \Ca\ Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Landec Corp \Ca\ stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,365 shares of LNDC stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,365
Previous 1,443
133.19%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding LNDC
# of Institutions
77Shares Held
20.2MCall Options Held
114KPut Options Held
82.1K-
Wynnefield Capital Inc New York, NY4.92MShares$00.0% of portfolio
-
Legion Partners Asset Management, LLC Los Angeles, CA2.95MShares$00.0% of portfolio
-
Greenhaven Road Investment Management, L.P. Greenwich, CT2.14MShares$00.0% of portfolio
-
22 Nw, LP Seattle, WA1.76MShares$00.0% of portfolio
-
325 Capital LLC New York, NY1.34MShares$00.0% of portfolio
About LANDEC CORP \CA\
- Ticker LNDC
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 29,595,600
- Description
- Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, a...